BERLIN--(Marketwired - May 07, 2013) - MagForce AG / MagForce AG Receives Further Patent
Related to NanoTherm® Therapy.
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* European patent granted for nanoparticle-drug conjugates
* MagForce further expands patent portfolio
MagForce AG (Frankfurt, XETRA: MF6), a leading
medical technology company in the field of nanomedicine in oncology,
today that the Company has been granted a further European patent for its
NanoTherm® therapy, for which the opposition period has now expired.
1871423 B1 relates to a new generation of NanoTherm® particles in the
nanoparticle-drug conjugates, which are suitable for drug delivery systems.
Nanoparticle-drug conjugates inside a tumor can be heated selectively by an
alternating magnetic field leading to a temperature-dependent release of
drug inside the tumor tissue producing a high local drug concentration.
Additionally the known synergistic effects of chemotherapy in combination
hyperthermia can be utilized.
"The locally limited and externally controllable drug release by means of
now patent-protected conjugates is expected to clearly reduce the mostly
considerable side-effects of conventional chemotherapeutic agents.
thermotherapy with nanoparticle-bound chemotherapy could also substantially
increase the effectiveness of the chemotherapeutic agent in tumor treatment
reduce the number of nanoparticles required to destroy the cancer cells,"
commented Prof. Dr. Hoda Tawfik, COO and co-CEO of MagForce. "We are very
pleased to have been granted a further patent for our NanoTherm®
expanding our patent portfolio we will improve protection of our
property and strengthen our competitive position."
About NanoTherm® Therapy
The NanoTherm® Therapy is a new approach for the local treatment
tumors. The principle of the method is the direct
superparamagnetic nanoparticles into a tumor and their subsequent heating
alternating magnetic field. The nanoparticles are extremely small
15 nanometers in diameter) and contain an iron oxide core with an
coating. The particles are activated by a magnetic field that
polarity 100,000 times per second, and heat is produced. Depending
duration of treatment and the achieved intratumoral temperatures, the
cells are either directly destroyed (thermal ablation) or
concomitant chemotherapy or radiotherapy (hyperthermia). With this
therapeutic approach, it is possible to combat the tumor from the inside
thereby sparing surrounding healthy tissue. The nanoparticles remain in
the treatment area, allowing for repeat treatments and the
multimodal therapy concepts. NanoTherm® Therapy has regulatory
approval in 27
About MagForce AG
MagForce AG is a leading medical technology company in the field of
in oncology. The Company's proprietary, NanoTherm® therapy,
targeted treatment of solid tumors through the intratumoral generation of
via activation of superparamagnetic nanoparticles. NanoTherm®,
and NanoActivator™ are components of the therapy and have received
regulatory approval as medical devices for the treatment of brain
MagForce, NanoTherm®, NanoPlan®, and NanoActivator™ are
MagForce AG in selected countries. For more information, please
This release may contain forward-looking statements and information which
identified by formulations using terms such as "expects", "aims",
"intends", "plans", "believes", "seeks", "estimates" or "will". Such
forward-looking statements are based on our current expectations
assumptions, which may be subject to a variety of risks and
results actually achieved by MagForce AG may substantially differ from
forward-looking statements. MagForce AG assumes no obligation to update
forward-looking statements or to correct them in case of developments,
differ from those, anticipated.
MagForce_Press Release_May 07, 2013:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MagForce AG via Thomson Reuters ONE